isoform-specific signaling. We first became interested in RSK as a potential substrate for PDK1 bound to the scaffold protein muscle A-kinase anchoring protein (mAKAP). 7 PDK1 activation of RSK was enhanced by co-expression with the mAKAP scaffold in a recombinant system. In cardiac myocytes, mAKAPβ (the alternatively spliced form expressed in muscle cells) organizes signalosomes that transduce cAMP, mitogenactivated protein kinase, Ca 2+ , and hypoxic signaling by binding a diverse set of enzymes, ion channels, and transcription factors. 8 We now show that type 3 RSK (RSK3) binds mAKAPβ directly via the unique N-terminal domain of RSK3, defining a novel enzyme-scaffold interaction. Our evidence supports a model in which anchored RSK3 regulates concentric cardiac myocyte growth, revealing an isoform-specific target for therapeutic intervention in pathologic cardiac hypertrophy.
Methods

Reagents
Commercial antibodies and oligonucleotides are listed in Online Tables VIII and IX. The commercially available RSK3 antibodies were of varying specificity (Online Figure I) . Additional reagents and detailed methods are provided in the Online Supplement.
RSK3 -/-Mouse
All experiments involving animals were approved by the Institutional Animal Care and Use Committee at the University of Miami. Constitutive RSK3 knockout mice were backcrossed to C57BL/6 mice over 10 generations. All experiments were performed with littermate controls and mice that were 8 to 10 weeks of age at the beginning of the study. Transverse aortic constriction was performed as A, p90 ribosomal S6 kinases (RSKs) contain 2 catalytic domains, N-terminal kinase domain (NTKD) and C-terminal kinase terminal (CTKD). 3 Only RSK3 has an N-terminal nuclear localization signal (NLS). In inactive RSK3, the CTKD binds the autoinhibitory domain (AID) α-helix.
Prebound to the D-domain, when activated, extracellular signal-regulated kinase (ERK) phosphorylates RSK3 residues including the CTKD activation loop (T 570 ). The CTKD then autophosphorylates S 377 , permitting phosphoinositide-dependent kinase 1 (PDK1) binding and phosphorylation of the NTKD activation loop (S 218 ). The NTKD phosphorylates RSK substrates. RSKs 1 to 4 were aligned and sequence similarity was calculated using Vector NTI AlignX (Invitrogen). RSK3 fragments used for mapping are indicated. B, Rat neonatal myocyte extract (lane 1, 0.2% total extract) was immunoprecipitated with preimmune (lane 2) or anti-VO56 mAKAP (lane 3) sera and detected using a pan-RSK antibody (C-20; see Online Figure I legend). C, HA-tagged kinases and myc-tagged mAKAPα were expressed by cotransfection of HEK293 cells and coimmunoprecipitated with anti-HA antibody. D, HA-tagged RSK3 fragments and myc-tagged mAKAPβ were expressed by cotransfection of COS-7 cells and coimmunoprecipitated with anti-HA antibody. n≥3 for each panel.
previously described, 9 and isoproterenol infusion was via Alzet 2002 osmotic pumps (Durect). Echocardiography was performed under isoflurane anesthesia on a Vevo 770 High-Resolution Imaging System (VisualSonics).
RNA Assays
mRNA species were assayed using NanoString technology, a direct and multiplexed measurement of gene expression without amplification, using fluorescent molecular bar codes and single-molecule imaging to identify and count multiple transcripts in a single reaction; 100 ng of RNA was hybridized in solution to a target-specific code set overnight at 65ºC, and individual mRNAs were counted using a NanoString Digital Analyzer.
Statistics
For all experiments, n refers to the number of individual mice or individual myocyte preparations. All data are expressed as mean ± SEM. P values were calculated using Student t tests and are not corrected for multiple comparisons. Repeated symbols represent P values of different orders of magnitude (ie, P<0.05, P<0.005, and others). All datasets involving multiple comparisons for which P values are provided also were significant by ANOVA (α=0.05).
Results
mAKAPβ: A Scaffold for RSK
We have previously published that RSK proteins and activity are associated with mAKAPα complexes in the brain. 7 We now show that RSK also is associated with mAKAPβ in cardiac myocytes ( Figure 1B ). To determine whether mAKAP preferentially binds a specific RSK isoform, hemagglutinin (HA)tagged RSK family members were co-expressed with mAKAP in HEK293 cells. In contrast to RSK1 and RSK2, RSK3 robustly mediated the coimmunoprecipitation of both mAKAPα and mAKAPβ ( Figure 1C and data not shown). RSK family members are similar in primary sequence with the exception of the extreme N-terminal and C-terminal domains and a small region after the hydrophobic motif ( Figure 1A ). Consistent with the selective binding of RSK3 to the scaffold, the N-terminal domain of RSK3 bound mAKAPβ ( Figure 1D ).
RSK3 Function in Neonatal Cardiac Myocytes
RSK family members can be activated in most cell types by ERK, but not c-Jun N-terminal kinases or p38. 3 ERK phosphorylation is permissive for PDK1 phosphorylation of the RSK N-terminal kinase domain, such that PDK1 phosphorylation of RSK S 218 is indicative of full activation of the enzyme ( Figure 1A ). To show that ERK activates RSK in cardiac myocytes, we treated neonatal rat ventricular myocytes with different hypertrophic agonists and mitogen-activated protein kinase pathway inhibitors and detected RSK activation using a pan-RSK S 218 phosphor-specific antibody (Online Figures  I and II) . The α-adrenergic stimulation with phenylephrine (PE) induced RSK phosphorylation 3-fold by both MEK1/2dependent (that activates ERK1/2) and MEK5-dependent (that activates ERK5) mechanisms (Online Figure II) . Moreover, MEK1/2 inhibition reduced RSK baseline phosphorylation. c-Jun N-terminal kinase and p38 inhibition did not affect PE activation and, in fact, variably increased baseline RSK phosphorylation. Fetal bovine serum and leukemia inhibitory factor also increased the level of activated RSK, but that occurred more so because of an increase in total RSK protein expression than because of ERK phosphorylation. Similar results were found for HA-tagged RSK3 (Figure 2A ). Acute PE treatment induced the phosphorylation of HA-RSK3 ERK (S 360 ) and PDK1 (S 218 ) sites through both MEK1/2-dependent and MEK5-dependent signaling. Together, these results confirmed that in cardiac myocytes ERK is responsible for RSK activation.
We have previously demonstrated that mAKAPβ complexes are required for the hypertrophy of cultured myocytes. [10] [11] [12] Therefore, we proposed the hypothesis that RSK3 signaling is a major determinant of cardiac myocyte growth. Neonatal myocytes were transfected with small interfering RNA oligonucleotides (siRNA) that diminished RSK3 mRNA and protein levels by >75% ( Figure 2B ). RSK3 siRNA did not induce the apoptosis of myocytes cultured either in the absence or in the presence of serum ( Figure 2C ). Importantly, in the presence of α-adrenergic stimulation, RSK3 siRNA inhibited morphologic hypertrophy by 34% and atrial natriuretic factor expression completely ( Figure 2D -2F and Online Figure III ). In addition, RSK3 siRNA had smaller, but detectable, effects on leukemia inhibitory factor and fetal bovine serum-stimulated hypertrophy. The results obtained by RSK3 RNA interference were confirmed with a second distinct RSK3 siRNA (data not shown).
Endogenous RSK3 proteins are expressed at a relatively low level in cardiac myocytes compared with the other RSK family members and are induced in expression by long-term PE treatment (Online Figure IVC) . As a result, RSK3 RNA interference did not affect the level of total RSK in the myocyte, only diminishing the RSK3 detected after immunoprecipitation with a specific RSK3 antibody ( Figure 2B and Online Figure IVC) . In control experiments, the inhibition of PE-induced hypertrophy by the RSK3 siRNA was rescued by the expression of recombinant HA-tagged human RSK3, but not by an inactive HA-RSK3 S 218 A mutant (Online Figure IVA and IVB). Remarkably, in these experiments, the cross-section area of unstimulated myocytes was increased by adenoviralbased expression of wild-type HA-RSK3 enzyme at a level comparable with that of endogenous RSK3 in PE-treated cells without affecting total RSK levels. Finally, to confirm that RSK activity was important for neonatal myocyte hypertrophy, we used the pan-RSK inhibitors BI-D1870 ( Figure 3 and Online Figure V ) and SL0101 (Online Figure VI) , [13] [14] [15] finding that, like RSK3 siRNA, these compounds inhibited agonistinduced myocyte hypertrophy.
High-Affinity RSK3 Binding Domain in mAKAP
We considered that the requirement for RSK3 in myocyte hypertrophy was attributable to the association of RSK3 with specific signaling complexes. To address this hypothesis, we defined the mAKAP domains responsible for RSK3 binding. HA-tagged RSK3 was co-expressed in heterologous cells with myc-tagged mAKAPβ fragments and coimmunoprecipitated using a myc-tag antibody ( Figure 4A and 4B). RSK3 preferentially associated with mAKAP amino acid residues 1286 to 1833, although it also weakly associated with mAKAP 245 to 587 and 525 to 1286. Consistent with this result, RSK3 binding to a full-length mAKAPβ protein with an internal deletion of residues 1257 to 1886 was reduced by >85%. Further mapping showed that the main RSK3 binding domain (RBD) of mAKAP mapped to a fragment encompassing residues 1694 to 1833 ( Figure 4C ). Accordingly, RSK3 bound poorly to a full-length mAKAPβ protein with an internal deletion of residues 1701 to 1800 ( Figure 4D ). As shown, the unique N-terminal domain of RSK3 bound full-length mAKAPβ ( Figure 1D ). The mAKAP RBD also bound HA-RSK3 1 to 42 ( Figure 4E ), but not to the N-terminally truncated RSK3 mutant (HA-RSK3 DN30) or the HA-tagged full-length RSK2 ( Figure 4F ). These results imply that the mAKAP RBD is responsible for the selective binding of RSK3 to mAKAP.
We next tested whether mAKAP-RSK3 binding is direct ( Figure 4G ). The binding of bacterially expressed His-tagged mAKAP 1286 to 1833 and full-length RSK3 was analyzed by surface plasmon resonance. The binding was direct and of high affinity (nanomolar K D ). We previously reported that once activated, RSK3 binds mAKAPα less well in cells. 7 Interestingly, previous RSK3 phosphorylation by either ERK or both ERK and PDK1 decreased the RSK3 binding affinity for mAKAP 5-fold and 8-fold, respectively, through a decrease in the association rate constant.
Disruption of RSK3 Anchoring Inhibits Neonatal Myocyte Hypertrophy
The identification of the high-affinity mAKAP RBD provided the opportunity to test whether anchoring of RSK3 is important for its function. When expressed in neonatal myocytes, a green fluorescent protein-mAKAP RBD fusion protein competed the association of endogenous RSK3 and mAKAPβ ( Figure 5A ). Expression of green fluorescent protein-mAKAP RBD fusion protein markedly inhibited PE-induced hypertrophy ( Figure 5B-5D ), similar to RSK3 siRNA ( Figure 2 ). Together, these results imply that RSK3 anchored to scaffolds through its unique N-terminal domain is required for the hypertrophy of cultured myocytes.
Role of RSK3 in Cardiac Hypertrophy In Vivo
The results obtained in vitro suggested that active RSK3 contributes to the development of pathologic myocyte hypertrophy. Further evidence supporting this hypothesis was obtained using a new RSK3 knockout mouse. By homologous recombination, stop codons were inserted into the second exon of the RSK3 (Rps6ka2) gene encoding the ATP-binding motif of the N-terminal kinase domain, 16 resulting in the constitutive absence of RSK3 protein in homozygous null mice (Online Figure VII) . In general, RSK3 -/mice appeared normal in morphology, were bred according to Mendelian genetics (Online Table I ), and exhibited no excess mortality up to 6 months of age (data not shown). Before any stress, the RSK3 -/mice had generally normal cardiac function, with the only measureable difference from wild-type littermates being a slight increase in left ventricular internal dimensions detected by echocardiography (Online Table II and Online Figure VIII ).
We tested whether RSK3 is required for compensated cardiac hypertrophy by subjecting the RSK3 -/mice to pressure overload for 2 weeks ( Figure 6A ). By echocardiography, transverse aortic constriction (TAC) induced a 36% increase in posterior wall thickness in wild-type mice, but only a 16% increase in RSK3 -/mice (Table 1 and Online Figure VIII) . The decreased hypertrophy was not accompanied by a change in contractility (fractional shortening). Postmortem gravimetric analysis showed that the corresponding increase in biventricular weight after TAC was similarly diminished in the knockout mice (48% for RSK3 +/+ vs 26% for RSK3 -/mice; Online Table III ). TAC primarily induces concentric growth of cardiac myocytes.
Inspection of wheat germ agglutinin-stained heart sections revealed that consistent with these results, RSK3 knockout attenuated the TAC-induced increase in myocyte transverse cross-section area by ≈46% ( Figure 6B and 6C) . Proportional results were obtained by morphometric analysis of adult cardiac myocytes isolated from the TAC mice ( Figure 6D-6G) .
To characterize the RSK3 -/cardiac phenotype at a molecular level, we surveyed for differences in the cardiac expression of 30 genes encoding proteins involved either in cardiac remodeling or in hypertrophic signaling ( Table 2) . Approximately two-thirds of the genes in our panel were significantly increased or decreased in expression by TAC. In general, the changes in expression were attenuated by RSK3 knockout. For example, TAC-induced atrial natriuretic factor expression was dramatically inhibited in RSK3 -/mice, consistent with the results obtained for PE-treated neonatal myocytes. Although after 2 weeks of pressure overload the small increases in cellular apoptosis and interstitial fibrosis detectable by histology for wild-type mice did not reach significance when compared with sham-operated controls (data not shown), these signs of remodeling tended to be less in the knockout mice (8.2±2.0 vs. 4.2±1.0×10 -4 TUNEL-positive nuclei and 0.49%±0.18% vs 0.29%±0.11% collagen staining for wild-type and RSK3 -/-TAC hearts, respectively). Interestingly, 2 genetic markers of fibrosis that were significantly induced in TAC wild-type mice, transforming growth factor β2 and collagen VI α1, 17 were attenuated in expression by RSK3 knockout ( Table 2) .
To further explore the role of RSK3 in cardiac hypertrophy, we used a second in vivo pathological stressor, chronic isoproterenol (Iso) infusion via subcutaneous osmotic pumps, and a physiological stressor, chronic exercise via swimming. Although Iso infusion resulted in a minor increase in ventricular wall thickness by echocardiography (Online Table IV) , at the cellular level Iso significantly induced myocyte growth in width in a RSK3-dependent manner as measured by histology and after myocyte isolation (Online Figure IX) . Unlike TAC, Iso infusion also induced eccentric growth, as evidenced by increased myocyte length and ventricular dilation by echocardiography (Online Tables IV and V) . This eccentric growth was not inhibited by RSK3 knockout. Together with the TAC data, these results demonstrate that RSK3 contributes to the induction of concentric myocyte hypertrophy in pathologic conditions.
Finally, RSK3 -/mice were exercised by swimming. As expected, 18 after swimming, wild-type mice exhibited a decreased resting heart rate (consistent with improved physical conditioning) and increased left ventricular internal dimensions (Online Table VI and Online Figure VIII) . After exercise, there were no significant differences between RSK3 knockout and wild-type mice detectable by echocardiography, and the cohorts exhibited a similar increase in biventricular weight indexed by body weight (6% and 7%, respectively; Online Table VII ).
Discussion
RSK activity is associated with the function of the nervous system, immunity, muscle, and cancer. 3 The roles of individual RSK family members, however, remain poorly defined. Human RSK2 mutations cause X-linked Coffin-Lowry syndrome, which includes mental and growth retardation and skeletal and facial anomalies, but rare cardiac abnormality. In the heart, RSK1 and RSK2 can activate the Na + /H + exchanger NHE1, and α-adrenergic-induced NHE1 phosphorylation is blocked by fmk, which inhibits all RSKs except RSK3. 19 We now reveal a role for RSK3 in the cardiovascular system, regulation of pathological myocyte hypertrophy.
Cardiac myocytes can grow in both width and length, termed concentric and eccentric hypertrophy, respectively. 1 Concentric myocyte hypertrophy involves the parallel assembly of contractile units (sarcomeres), increasing potential myocyte tension and wall thickness. In contrast, eccentric myocyte hypertrophy involves the serial assembly of sarcomeres along the axis of contraction, mainly contributing to increased ventricular wall area. We found that RSK3 was required for TAC-induced concentric hypertrophy, as well as for Iso-induced myocyte growth in width in vivo. These differences can be modeled in vitro. Interleukin-6 cytokines such as leukemia inhibitory factor and cardiotrophin-1 induce an elongated and eccentric phenotype for cultured neonatal myocytes, in contrast to the symmetric growth stimulated by PE. 20 Interestingly, the growth of the cultured myocytes tended to depend on RSK3 more when induced by α-adrenergic stimulation than by leukemia inhibitory factor (Figures 2 and 3) . The greater inhibition of PE-induced morphologic hypertrophy was consistent with the more robust activation of RSK by PE than leukemia inhibitory factor (Online Figure II) , as well as the results obtained in vivo.
RSK3 was activated in myocytes by ERK1, ERK2, and ERK5 (Figure 2A) . Whereas RSK3 has been absent from the cardiac literature, ERK signaling has been well-studied both in human disease and in animal models. The autosomal-dominant human syndromes Noonan, Costello, cardiofaciocutaneous, and LEOPARD result from mutations in PTPN11, HRAS, RAF1, BRAF, MEK1, and MEK2 that activate ERK1/2 signaling. 21 These Rasopathies feature developmental delay, dysmorphic features, and defects in multiple organ systems, often including a hypertrophic phenotype. 22 In mice, left ventricular hypertrophy has been induced by cardiac myocyte-specific expression of constitutively active H-Ras and MEK1, as well as cardiac-specific deletion of the Ras GTPase-activating protein neurofibromin that inhibits Ras signaling. 23, 24 Conversely, transgenic expression of dominant-negative Raf1 inhibited the hypertrophy due to pressure overload.
Recently, the Molkentin group showed that cardiac myocyte-specific knockout of all 4 ERK1/2 alleles resulted in a severe, fatal dilated cardiomyopathy without increased myocyte death. 25 ERK1/2-null myocytes were longer and narrower than those from control animals. PTPN11 (Shp2) knockout that decreased ERK1/2 activation also resulted in an elongated myocyte morphology and dilated cardiomyopathy. 26 Total mouse heart RNA was assayed by NanoString technology for the indicated mRNAs and normalized by the data for GAPDH. All data (mean ± SEM) are fold-expression compared with the sham +/+ cohort. n = 5 for all cohorts. *P values comparing -/-vs +/+; † P values comparing TAC and sham-operated for the same genotype. Analysis of the complete dataset showed that gene expression for the sham and the TAC RSK3 -/cohorts were highly correlated (Pearson r≥99%); in contrast, the TAC RSK3 +/+ dataset diverged from the other 3 cohorts (r<93%). ANOVA (2-factor with replication) comparing the TAC datasets: P=0.05 for -/-vs. +/+; P=3.3 ×10 -14 for interaction between genes and cohorts.
Conversely, myocytes from constitutively active MEK1 transgenic mice were shorter and wider. 25 In contrast to the ERK1/2 and Shp2 knockout mice, we found that deletion of the downstream effector RSK3 resulted in a milder phenotype, with the defect in concentric growth significant only after TAC and Iso infusion. Together, these observations are consistent with the hypothesis that ERK1/2 signaling through RSK3 promotes stress-induced concentric growth of cardiac myocytes independently of other signaling pathways that regulate eccentric hypertrophy.
We found that RSK3 was activated in myocytes by not only ERK1/2 but also ERK5. There is evidence that MEK5-ERK5 signaling primarily induces eccentric myocyte hypertrophy, 27 although ERK5 also may contribute to concentric growth. 28 Whether RSK3 induces hypertrophy in response to both ERK5 and ERK1/2 will require further investigation, especially because mAKAPβ preferentially binds MEK5 and ERK5. 12 The data obtained using the RSK knockout mouse establish a function for RSK3 in pathological remodeling. However, we cannot completely exclude a role for RSK3 in physiologic hypertrophy. For example, the myocytes isolated from unstressed RSK3 -/mice tended to be smaller in both width and length ( Figure 6 and Online Figure  IX ). In addition, after swimming, RSK3 -/biventricular weight was less than that of wild-type mice, albeit not significantly after normalization by body weight (Online Table VII ).
It is remarkable that even though RSK3 constitutes a minority of the total RSK in the myocyte (Online Figures  IV and X) , RSK3 activity is, nevertheless, required for myocyte growth. The differential anchoring of RSK3 by scaffold proteins provides a mechanism by which RSK3 may specifically function in vivo. Scaffolds are likely to be most important for enzymes such as RSK3 that are low in abundance and that have broad intrinsic substrate specificity. RSK protein kinases catalyze the phosphorylation of RxRxx(S/T) sites and overlap in specificity with other AGC kinases. 3 By co-localizing enzymes, their upstream activators, and substrate effectors, scaffolds can accelerate the kinetics of signaling, amplify responses, increase specificity in enzyme catalysis, and direct signaling to specific subcellular compartments. 29 Little is known about RSK compartmentation in cells or participation in multimolecular signaling complexes. On mitogen stimulation, cytosolic RSK1 (and potentially other RSK isoenzymes) can transiently translocate to the plasma membrane, whereas activated RSK tends to be enriched in the nucleus. 3 In neurons, RSKs bind PDZ domain-containing proteins via their conserved C-terminal STxL peptides, directing the kinases to substrates involved in synaptic transmission. 30 By another mechanism, RSK1 binds type 1 protein kinase A and D-AKAP-1, a mitochondrion-localized scaffold. 31, 32 Consistent with the fact that we can only detect RSK3 in myocytes after immunoprecipitation, we have not been able to detect endogenous RSK3 protein by immunocytochemistry. When overexpressed at a low level, HA-RSK3 was enriched at the nuclear envelope (data not shown), the predominant location for mAKAPβ in the cardiac myocyte. 33 By characterizing in detail the protein-protein interaction between the unique RSK3 N terminus and mAKAPβ, we have identified a new mechanism by which RSK3 can be specifically anchored by ≥1 scaffolds that may be targeted to different signaling compartments. We demonstrated the functional significance of this RSK3 anchoring using a competing binding peptide (mAKAP RBD) that inhibited myocyte hypertrophy. Moreover, because the binding of RSK3 to mAKAP was inhibited by RSK3 phosphorylation, it is likely that RSK3 anchoring to this and other scaffolds will be regulated in cells.
RSK3 anchoring by scaffolds should specify the phosphorylation of select substrates. Because the affinity of RSK3 for mAKAPβ is decreased after its activation, it is possible that mAKAPβ-associated RSK3 is responsible for phosphorylating substrates both adjacent to and at a distance from the scaffold (Online Figure XI) . Although our initial screen of known RSK substrates did not identify any that were less phosphorylated in RSK3 -/mice (Online Figure  X and data not shown), mAKAPβ-associated RSK3 may be important for nuclear phosphorylation events involved in cardiac remodeling because of the location of the scaffold. Alternatively, proteins phosphorylated by RSK family members also include those involved in the regulation of translation and metabolism, as well as sarcomeric proteins. 3 Besides co-localizing enzymes and substrates, scaffolds can facilitate cross-talk between different signaling pathways. mAKAPβ also organizes cAMP, Ca 2+ -dependent, and hypoxic signaling modules, and it is required for calcineurin-nuclear factor of activated T cells-dependent myocyte hypertrophy. 8 Future work will be required to elucidate which mAKAPβ binding partners are present in individual mAKAPβ signalosomes and whether RSK3 and the other enzymes co-regulate downstream effectors.
The regulation of NHE1 by RSK1/2 has spurred recent interest in using RSK inhibitors to treat heart disease. 34 Our results should encourage that line of research because RSK3 knockout reduced TAC-induced hypertrophy without diminishing cardiac function and while inhibiting the expression of genetic markers for pathological remodeling. RSK inhibition may have multiple applications, including its use in acquired diseases such as hypertension (pressure overload) and for the treatment of the aforementioned Rasopathies. Recently, a Noonan syndrome mouse model (Raf1 L 613 V knock-in) mouse was treated with PD0325901, resulting in the attenuated progression of cardiac hypertrophy cardiomyopathy and other Noonan characteristics. 21 The use of MEK inhibitors in humans is currently being tested in clinical trials for cancer. Results have not been entirely encouraging, however, and trials with PD0325901 have been terminated early because of ophthalmologic and neurologic toxicity. 22 Targeting of RSK3 may be an alternative approach to avoid some of the harmful side effects of global ERK pathway inhibition. The use of RSK3 inhibitors that either competitively bind the active site or disrupt anchoring should be explored as potential novel cardiac therapies.
